儿童系统性红斑狼疮的治疗进展

Progress in the Treatment of Systemic Lupus Erythematosus in Children

儿童系统性红斑狼疮(cSLE)指在18岁之前出现,以多系统、多器官损害为特征的自身免疫性疾病,占总发病患者数的15%~20%。与成人患者相比,儿童患者疾病活动性更高,更具侵袭性,更易出现肾脏、血液及中枢神经系统受累,器官损伤更严重,预后更差。近年来,关于cSLE治疗方面的研究越来越多,随着治疗理念和新型免疫抑制剂尤其是生物制剂的应用,cSLE预后得到改善。本文综述了cSLE的治疗研究进展,以期为临床cSLE患儿的治疗提供一定理论基础。

Childhood-onset systemic lupus erythematosus(cSLE)refers to an autoimmune disease that appears before the age of 18 and is characterized by multi-system and multi-organ damage,accounting for about 15%to 20%of the total number of cases.Compared with adult-onset patients,pediatric patients have higher disease activity,more aggressive disease,more kidney,blood,and central nervous system involvement,more severe organ damage,and worse prognosis.In recent years,more and more studies have been conducted on the treatment of cSLE.With the application of therapeutic concepts and new immunosuppressants,especially biological agents,the prognosis of cSLE has been improved.This article reviews the progress in the treatment of cSLE to provide some theoretical help for the treatment of clinical cSLE children.